Meta-analyses of randomized trials show SGLT2 inhibitor drugs slow progression of chronic kidney disease.
It’s becoming clear that this class of drugs does much more than just treat diabetes.
Chronic kidney disease is a major risk factor for heart disease.
Slowing its progression not only protects the kidneys, but the whole cardiovascular system as well.



